Clinical Topics & News
Literature Review
Relapsing, progressive MS classifications should be abandoned
“The disease appears to be more of a continuum of disability progression, which is sometimes also accompanied by relapses.”
News
FDA approves Uplizna for treatment of anti-AQP4 antibody–positive NMOSD
Second FDA-approved therapy for neuromyelitis optica spectrum disorder offers patients additional treatment option.
News
Neurologists’ pay gets a boost, most happy with career choice
Neurologists’ average annual income this year rose to $280,000, up from $267,000 last year.
News
Database will collect data on COVID-19 in patients with MS
A registry is gathering information on patients throughout the United States with a view to understanding outcomes and improving treatment.
News
FDA removes pregnancy category C warning from certain MS medications
Labeling updates include more information on using certain MS drugs during pregnancy and breastfeeding.
News
FDA approves ozanimod for relapsing and secondary progressive forms of MS
It is the only approved sphingosine-1-phosphate receptor modulator with no requirement for genetic testing or label-based first-dose observation...
Literature Review
Serum levels of neurofilament light are increased before clinical onset of MS
The findings support the existence of a prodromal phase of MS and could facilitate early diagnosis and treatment.
News
Medicaid spending on MS drugs rose despite introduction of generic glatiramer
“Although some of this increase is attributable to the 2014 Medicaid expansion, the primary driver was rising DMT costs per prescription, which...
News
First generics for Gilenya approved by FDA
Approvals for fingolimod generics were issued to three companies.